Readystate Asset Management LP Sells 196,841 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Readystate Asset Management LP reduced its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 85.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 34,353 shares of the company’s stock after selling 196,841 shares during the period. Readystate Asset Management LP’s holdings in NewAmsterdam Pharma were worth $977,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Arizona State Retirement System raised its stake in shares of NewAmsterdam Pharma by 3.8% in the third quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock worth $377,000 after purchasing an additional 483 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in NewAmsterdam Pharma by 2.4% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock worth $408,000 after buying an additional 521 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in NewAmsterdam Pharma by 5.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after buying an additional 544 shares during the last quarter. Knights of Columbus Asset Advisors LLC lifted its stake in NewAmsterdam Pharma by 2.4% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 33,610 shares of the company’s stock valued at $956,000 after acquiring an additional 777 shares during the period. Finally, Mather Group LLC. purchased a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at about $28,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 75,117 shares of the stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the completion of the sale, the chief accounting officer owned 15,000 shares in the company, valued at approximately $543,150. This trade represents a 83.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the transaction, the insider directly owned 73,481 shares in the company, valued at approximately $2,443,243.25. This represents a 7.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 298,647 shares of company stock valued at $10,236,050 in the last ninety days. 20.84% of the stock is currently owned by insiders.

NewAmsterdam Pharma Stock Up 1.5%

NAMS stock opened at $35.76 on Thursday. The business’s 50-day moving average price is $34.03 and its 200-day moving average price is $32.43. The stock has a market cap of $4.05 billion, a P/E ratio of -17.44 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The firm had revenue of $0.03 million for the quarter. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. On average, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

NAMS has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Leerink Partners restated an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. The Goldman Sachs Group lifted their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Stifel Nicolaus increased their target price on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Royal Bank Of Canada boosted their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.18.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.